Osteoporosis often called a “silent” disease, is a significant health burden worldwide and associated with pain and decreased physical, social, and mental well-being.
According to the National Institute of Health Osteoporosis and Related Bone Diseases National Resource Center, “in the United States, more than 53 million people either already have osteoporosis or are at high risk due to low bone mass”. Similarly, as per DelveInsight’s analysis, the total diagnosed prevalent population of osteoporosis in the seven major markets was found to be 28,000,000+ in 2017, which is expected to increase in the coming years. Among the EU5 countries, Germany had the maximum diagnosed prevalent population of osteoporosis, followed by Italy, while France had the lowest number of diagnosed prevalent cases of osteoporosis.
Osteoporosis, directly and indirectly, affects the physical and mental health of the person and their families. It can also lead to a significant risk of death and complications. However, owing to the positive outcomes of the few products in the developmental stage by key players in the osteoporosis market such as Amgen and Haoma Medica, the treatment pattern is expected to make a significant positive shift in the coming years. For more details, visit: Osteoporosis Symptoms, Diagnosis, Key Companies and Treatments Options